Genitourinary Cancers Clinical Trials & Research at St. Joseph Health
Medical Group
St. Joseph Health Medical Group is currently enrolling patients for the
following genitourinary cancers clinical trials:
Urothelial Cancer
Prostate Cancer
Renal Cell Cancer
Urothelial
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab
versus Standard of Care Chemotherapy in Participants with Previously Untreated
Unresectable or Metastatic Urothelial Cancer (CheckMate 901)
Treatment agent: Nivolumab + ipilimumab/SOC
PI:
Thomas Stanton, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03036098
An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab
Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG)
Treatment agent: Durvalumab
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03084471
Prostate
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic
Castration-resistant Prostate Cancer Associated with Homologous Recombination
Deficiency (TRITON2)
Treatment agent: Rucaparib (PARPi)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT02952534
A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus
Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant
Prostate Cancer Associated with Homologous Recombination Deficiency (TRITON3)
Treatment agent: Rucaparib (PARPi)
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT02975934
Renal Cell
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing
CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib
(Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma
(JIT Calithera)
Treatment agent: CB-839 (glutaminase inhibitor) +/- Cabozantinib
PI:
Thomas Stanton, MD
Study Coordinator: Teresa Lund //
Teresa.Lund@stjoe.org // (707) 521-3803
Resources and Links:
clinicaltrials.gov NCT No: NCT03428217